| DB ID | MyCo_3289 |
| Title | Blood basophil activation is a reliable biomarker of allergic bronchopulmonary aspergillosis in cystic fibrosis |
| Year | 2015 |
| PMID | 26585435 |
| Fungal Diseases involved | Allergic bronchopulmonary aspergillosis |
| Associated Medical Condition | Cystic fibrosis |
| Genus | Aspergillus |
| Species | fumigatus |
| Organism | Aspergillus fumigatus |
| Ethical Statement | None |
| Site of Infection | None |
| Opportunistic invasive | None |
| Sample type | Body fluid |
| Sample source | Blood |
| Host Group | Human |
| Host Common name | Human |
| Host Scientific name | Homo sapiens |
| Biomarker Name | Basophil CD203c |
| Biomarker Full Name | Basophil CD203c |
| Biomarker Type | Diagnostic |
| Biomolecule | Protein |
| Geographical Location | USA |
| Cohort | A prospective 2-year longitudinal cohort design was employed at Stanford University Medical Center (Stanford, CA, USA) while a cross-sectional validation cohort was enrolled at the Royal College of Surgeons Beaumont Hospital Cystic Fibrosis Center (Dublin, Ireland). Here conducted a prospective longitudinal study (Stanford cohort) comparing basophil activation test CD203c levels by flow cytometry before and after activation with Aspergillus fumigatus allergen extract or recombinant Asp f1 in 20 CF patients with ABPA (CF-ABPA) and in two comparison groups: CF patients with A. fumigatus colonisation (AC) but without ABPA (CF-AC; n=13) and CF patients without either AC or ABPA (CF; n=12). |
| Cohort No. | 20 |
| Age Group | None |
| P Value | p<0.0001 |
| Sensitivity | None |
| Specificity | None |
| Positive Predictive Value | None |
| MIC | None |
| Fold Change | None |
| Pathway | None |
| Disease Introduction Mechanism | None |
| Technique | Analytic |
| Analysis Method | Flow Cytometry Analysis |
| ELISA kits | None |
| Assay Data | None |
| Validation Techniques used | Flow Cytometry Analysis |
| Up Regulation Down Regulation | Positive |
| Sequence Data | None |
| External Link | None |
